GlaxoSmithKline Is Taking a Tough Approach to Budgets

GlaxoSmithKline Is Taking a Tough Approach to Budgets


This is believed to be at least partly due to the company's new chief executive officer, Emma Walmsley, who has helmed the company for about 12 months now, and her tougher commercial approach to the company's growth. The budget cuts go along with recent cuts to the company's research-and development operations.



from Biotech News